Citigroup’s Processa Pharmaceuticals PCSA Stock Holding History

Citigroup’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14	Closed	-$35	–	6123
2026 Q1	$35	Buy	+14	New	+$38	﹤0.01%	5668
2025 Q4	–	Sell	-1,362	Closed	-$6.53K	–	6355
2025 Q3	$6.53K	Buy	+1,362	New	+$7.19K	﹤0.01%	5148

Other funds holding PCSA

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's PCSA Position: Q2 2026 in Review

Citigroup sold out of Processa Pharmaceuticals (PCSA) in Q2 2026, closing a stake of 14 shares — an estimated $35 sold.

Citigroup first reported a position in PCSA in Q3 2025 and held it in 2 quarters. The position peaked at $6.53K in Q3 2025. 12 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

Citigroup reported no remaining Processa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citigroup sold 14 Processa Pharmaceuticals shares in Q2 2026, an estimated $35.
Citigroup first reported a position in Processa Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Citigroup's Processa Pharmaceuticals position peaked at $6.53K in Q3 2025.
12 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.